VECT VectivBio Holding AG

FDA Catalyst Company
6.3
-0.25  -4%
Previous Close 6.55
Open 6.75
52 Week Low 2.7426
52 Week High 16.75
Market Cap $226,632,036
Shares 35,973,339
Float 23,006,169
Enterprise Value $133,206,370
Volume 10,215
Av. Daily Volume 17,931
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Credit Suisse Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/04/2021
B of A Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/04/2021
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/04/2021

Latest News

  1. BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV. Company management will also be participating in one-on-one investor meetings at the conference on Wednesday, May 11, 2022.

    Bank of America 2022 Healthcare Conference
    Date: Wednesday, May 11, 2022
    Time: 4:40 p.m. PT / 7:40 p.m. ET
    Webcast: Click here

    An archived replay of the webcast will be available for 30 days following…

    View Full Article
  2. BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment of Patrick Malloy as Senior Vice President, Investor Relations and Strategic Communications.  Mr. Malloy's two decades of investor relations and commercial leadership experience strengthens VectivBio as it continues to evolve into a fully integrated, rare disease leader. 

    "Pat has a broad range of experience in not only investor relations, but also commercial and strategic leadership in the biotech and rare disease spaces," said Luca Santarelli, M.D., Founder and CEO of VectivBio. "As we…

    View Full Article
  3. Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022

    STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023

    Cash Runway Extends Beyond Anticipated Release of Topline STARS Phase 3 Data

    Management to Host Conference Call Today at 8.00 a.m. ET

    BASEL, Switzerland, April 07, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today reported financial results and provided a business update for the full year ended December 31, 2021.

    "Since our…

    View Full Article
    • Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial milestones and double-digit royalties on apraglutide sales in Japan
    • Loan facility established with Kreos Capital, a leading global growth lender to life sciences and healthcare companies, granting the company access of up to $75 million, with a minimum commitment to draw down $10 million
    • VectivBio to hold FY 2021 Earnings Call and Business Update on April 7, 2022, at 8:00 a.m. ET

    BASEL, Switzerland, March 30, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational…

    View Full Article
  4. -- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease --

    -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available therapies --

    BASEL, Switzerland, March 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today presented new clinical data demonstrating the potential of apraglutide, a next-generation, long-acting GLP-2 analog, as a novel treatment for short bowel syndrome with intestinal failure (SBS-IF) patients who have impaired renal function. The data were presented as a…

    View Full Article
View All VectivBio Holding AG News